CD30 ligand is a target for a novel biological therapy against colitis associated with Th17 responses

Journal of Immunology

Volumn 185, Issue 12, 2010, Pages 7671-7680

  Sun, Xun ^a,b   Yamada, Hisakata ^a   Shibata, Kensuke ^a   Muta, Hiromi ^a   Tani, Kenzaburo ^a   Podack, Eckhard R ^c   Iwakura, Yoichiro ^d   Yoshikai, Yasunobu ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b CHINA MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD30 LIGAND; DEXTRAN SULFATE; GAMMA INTERFERON; HYBRID PROTEIN; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELLULAR IMMUNITY; COLITIS; CYTOKINE PRODUCTION; DRUG TARGETING; HISTOPATHOLOGY; IMMUNOMODULATION; IN VITRO STUDY; LYMPHOCYTE DIFFERENTIATION; MALE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SURVIVAL RATE; TH17 CELL; WEIGHT REDUCTION; WILD TYPE;

ACUTE DISEASE; ANIMALS; ANTIGENS, CD30; CD30 LIGAND; CELL COMMUNICATION; CELL DIFFERENTIATION; CHRONIC DISEASE; COLITIS; CYTOKINES; DEXTRAN SULFATE; FEMALE; HUMANS; IMMUNOGLOBULINS; MALE; MICE; MICE, INBRED BALB C; MICE, KNOCKOUT; MICE, SCID; MUCOUS MEMBRANE; RECOMBINANT FUSION PROTEINS; SIGNAL TRANSDUCTION; TH17 CELLS;

EID: 78650652886     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1002229     Document Type: Article

References (44)

1. Smith, C. A., H. J. Gruss, T. Davis, D. Anderson, T. Farrah, E. Baker, G. R. Sutherland, C. I. Brannan, N. G. Copeland, N. A. Jenkins, et al. 1993. CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 73:1349-1360.
2. Shimozato, O., K. Takeda, H. Yagita, and K. Okumura. 1999. Expression of CD30 ligand (CD153) on murine activated T cells. Biochem. Biophys. Res. Commun. 256:519-526.
3. Kennedy, M. K., C. R. Willis, and R. J. Armitage. 2006. Deciphering CD30 ligand biology and its role in humoral immunity. Immunology 118:143-152.
4. Lane, P. J., F. M. Gaspal, and M. Y. Kim. 2005. Two sides of a cellular coin: CD4 (+) CD3-cells regulate memory responses and lymph-node organization. Nat. Rev. Immunol. 5:655-660.
5. Dürkop, H., U. Latza, M. Hummel, F. Eitelbach, B. Seed, and H. Stein. 1992. Molecular cloning and expression of a new member of the nerve growth factor receptor family that is characteristic for Hodgkin's disease. Cell 68:421-427.
6. Ellis, T. M., P. E. Simms, D. J. Slivnick, H. M. Jäck, and R. I. Fisher. 1993. CD30 is a signal-transducing molecule that defines a subset of human activated CD45RO+ T cells. J. Immunol. 151:2380-2389.
7. Bowen, M. A., R. K. Lee, G. Miragliotta, S. Y. Nam, and E. R. Podack. 1996. Structure and expression of murine CD30 and its role in cytokine production. J. Immunol. 156:442-449.
8. Siegmund, T., N. Armitage, L. S. Wicker, L. B. Peterson, J. A. Todd, and P. A. Lyons. 2000. Analysis of the mouse CD30 gene: a candidate for the NOD mouse type 1 diabetes locus Idd9.2. Diabetes 49:1612-1616.
9. Flórido, M., M. Borges, H. Yagita, and R. Appelberg. 2004. Contribution of CD30/CD153 but not of CD27/CD70, CD134/OX40L, or CD137/4-1BBL to the optimal induction of protective immunity to Mycobacterium avium. J. Leukoc. Biol. 76:1039-1046.
10. Polte, T., A. K. Behrendt, and G. Hansen. 2006. Direct evidence for a critical role of CD30 in the development of allergic asthma. J. Allergy Clin. Immunol. 118:942-948.
11. Blazar, B. R., R. B. Levy, T. W. Mak, A. Panoskaltsis-Mortari, H. Muta, M. Jones, M. Roskos, J. S. Serody, H. Yagita, E. R. Podack, and P. A. Taylor. 2004. CD30/CD30 ligand (CD153) interaction regulates CD4+ T cell-mediated graft-versus-host disease. J. Immunol. 173:2933-2941.
12. Sun, X., H. Yamada, K. Shibata, H. Muta, K. E. R. Tani, Y. Podack Iwakura, and Y. Yoshikai. 2010. CD30 ligand/CD30 plays a critical role in Th17 differentiation in mice. J. Immunol. 185:2222-2230.
13. Strober, W., I. J. Fuss, and R. S. Blumberg. 2002. The immunology of mucosal models of inflammation. Annu. Rev. Immunol. 20:495-549.
14. Bouma, G., and W. Strober. 2003. The immunological and genetic basis of inflammatory bowel disease. Nat. Rev. Immunol. 3:521-533.
15. Kaser, A., S. Zeissig, and R. S. Blumberg. 2010. Inflammatory bowel disease. Annu. Rev. Immunol. 28:573-621.
16. Dieleman, L. A., M. J. Palmen, H. Akol, E. Bloemena, A. S. Peña, S. G. Meuwissen, and E. P. Van Rees. 1998. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin. Exp. Immunol. 114:385-391.
17. Fichtner-Feigl, S., I. J. Fuss, J. C. Preiss, W. Strober, and A. Kitani. 2005. Treatment of murine Th1-and Th2-mediated inflammatory bowel disease with NF-κ B decoy oligonucleotides. J. Clin. Invest. 115:3057-3071.
18. Powrie, F., R. Correa-Oliveira, S. Mauze, and R. L. Coffman. 1994. Regulatory interactions between CD45RBhigh and CD45RBlow CD4+ T cells are important for the balance between protective and pathogenic cell-mediated immunity. J. Exp. Med. 179:589-600.
19. Fina, D., M. Sarra, M. C. Fantini, A. Rizzo, R. Caruso, F. Caprioli, C. Stolfi, I. Cardolini, M. Dottori, M. Boirivant, et al. 2008. Regulation of gut inflammation and th17 cell response by interleukin-21. Gastroenterology 134:1038-1048.
20. Takedatsu, H., K. S. Michelsen, B. Wei, C. J. Landers, L. S. Thomas, D. Dhall, J. Braun, and S. R. Targan. 2008. TL1A (TNFSF15) regulates the development of chronic colitis by modulating both T-helper 1 and T-helper 17 activation. Gastroenterology 135:552-567.
21. Zhang, Z., M. Zheng, J. Bindas, P. Schwarzenberger, and J. K. Kolls. 2006. Critical role of IL-17 receptor signaling in acute TNBS-induced colitis. Inflamm. Bowel Dis. 12:382-388.
22. Ito, R., M. Kita, M. Shin-Ya, T. Kishida, A. Urano, R. Takada, J. Sakagami, J. Imanishi, Y. Iwakura, T. Okanoue, et al. 2008. Involvement of IL-17A in the pathogenesis of DSS-induced colitis in mice. Biochem. Biophys. Res. Commun. 377:12-16.
23. O'Connor, W. J., Jr., M. Kamanaka, C. J. Booth, T. Town, S. Nakae, Y. Iwakura, J. K. Kolls, and R. A. Flavell. 2009. A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat. Immunol. 10:603-609.
24. Ogawa, A., A. Andoh, Y. Araki, T. Bamba, and Y. Fujiyama. 2004. Neutralization of interleukin-17 aggravates dextran sulfate sodium-induced colitis in mice. Clin. Immunol. 110:55-62.
25. Yang, X. O., S. H. Chang, H. Park, R. Nurieva, B. Shah, L. Acero, Y. H. Wang, K. S. Schluns, R. R. Broaddus, Z. Zhu, and C. Dong. 2008. Regulation of inflammatory responses by IL-17F. J. Exp. Med. 205:1063-1075.
26. Boirivant, M., I. J. Fuss, A. Chu, and W. Strober. 1998. Oxazalone colitis: a murine model of T helper cell type 2 colitis treatable with antibodies to interleukin 4. J. Exp. Med. 188:1929-1939.
27. Sadlack, B., H. Merz, H. Schorle, A. Schimpl, A. C. Feller, and I. Horak. 1993. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 75:253-261.
28. Mombaerts, P., E. Mizoguchi, M. J. Grusby, L. H. Glimcher, A. K. Bhan, and S. Tonegawa. 1993. Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice. Cell 75:274-282.
29. Sun, X., S. Somada, K. Shibata, H. Muta, H. Yamada, H. Yoshihara, K. Honda, K. Nakamura, R. Takayanagi, K. Tani, et al. 2008. A critical role of CD30 ligand/CD30 in controlling inflammatory bowel diseases in mice. Gastroenterology 134:447-458.
30. Dieleman, L. A., B. U. Ridwan, G. S. Tennyson, K. W. Beagley, R. P. Bucy, and C. O. Elson. 1994. Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice. Gastroenterology 107:1643-1652.
31. Nishimura, H., T. Yajima, H. Muta, E. R. Podack, K. Tani, and Y. Yoshikai. 2005. A novel role of CD30/CD30 ligand signaling in the generation of longlived memory CD8+ T cells. J. Immunol. 175:4627-4634.
32. Nakae, S., Y. Komiyama, A. Nambu, K. Sudo, M. Iwase, I. Homma, K. Sekikawa, M. Asano, and Y. Iwakura. 2002. Antigen-specific T cell sensitization is impaired in IL-17-deficient mice, causing suppression of allergic cellular and humoral responses. Immunity 17:375-387.
33. Obermeier, F., N. Dunger, L. Deml, H. Herfarth, J. Schölmerich, and W. Falk. 2002. CpG motifs of bacterial DNA exacerbate colitis of dextran sulfate sodiumtreated mice. Eur. J. Immunol. 32:2084-2092.
34. Yoshihara, K., T. Yajima, C. Kubo, and Y. Yoshikai. 2006. Role of interleukin 15 in colitis induced by dextran sulphate sodium in mice. Gut 55:334-341.
35. Karasuyama, H., and F. Melchers. 1988. Establishment of mouse cell lines which constitutively secrete large quantities of interleukins 2, 3, 4, or 5, using modified cDNA expression vectors. Eur. J. Immunol. 18:97-104.
36. Tang, C., H. Yamada, K. Shibata, H. Muta, W. Wajjwalku, E. R. Podack, and Y. Yoshikai. 2008. A novel role of CD30L/CD30 signaling by T-T cell interaction in Th1 response against mycobacterial infection. J. Immunol. 181:6316-6327.
37. Fujino, S., A. Andoh, S. Bamba, A. Ogawa, K. Hata, Y. Araki, T. Bamba, and Y. Fujiyama. 2003. Increased expression of interleukin 17 in inflammatory bowel disease. Gut 52:65-70. (Pubitemid 36020767)
38. Yen, D., J. Cheung, H. Scheerens, F. Poulet, T. McClanahan, B. McKenzie, M. A. Kleinschek, A. Owyang, J. Mattson, W. Blumenschein, et al. 2006. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J. Clin. Invest. 116:1310-1316.
39. Atarashi, K., J. Nishimura, T. Shima, Y. Umesaki, M. Yamamoto, M. Onoue, H. Yagita, N. Ishii, R. Evans, K. Honda, and K. Takeda. 2008. ATP drives lamina propria T (H) 17 cell differentiation. Nature 455:808-812.
40. Laurence, A., C. M. Tato, T. S. Davidson, Y. Kanno, Z. Chen, Z. Yao, R. B. Blank, F. Meylan, R. Siegel, L. Hennighausen, et al. 2007. Interleukin-2 signaling via STAT5 constrains T helper 17 cell generation. Immunity 26:371-381.
41. Lee, S. Y., S. Y. Lee, G. Kandala, M. L. Liou, H. C. Liou, and Y. Choi. 1996. CD30/TNF receptor-associated factor interaction: NF-kappa B activation and binding specificity. Proc. Natl. Acad. Sci. USA 93:9699-9703.
42. Duckett, C. S., R. W. Gedrich, M. C. Gilfillan, and C. B. Thompson. 1997. Induction of nuclear factor kappaB by the CD30 receptor is mediated by TRAF1 and TRAF2. Mol. Cell. Biol. 17:1535-1542.
43. O'Connor, R. A., C. T. Prendergast, C. A. Sabatos, C. W. Lau, M. D. Leech, D. C. Wraith, and S. M. Anderton. 2008. Cutting edge: Th1 cells facilitate the entry of Th17 cells to the central nervous system during experimental autoimmune encephalomyelitis. J. Immunol. 181:3750-3754.
44. Oyamada, A., H. Ikebe, M. Itsumi, H. Saiwai, S. Okada, K. Shimoda, Y. Iwakura, K. I. Nakayama, Y. Iwamoto, Y. Yoshikai, and H. Yamada. 2009. Tyrosine kinase 2 plays critical roles in the pathogenic CD4 T cell responses for the development of experimental autoimmune encephalomyelitis. J. Immunol. 183:7539-7546.